Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene versus fulvestrant for ESR1-mutated ER-positive/HER2-negative advanced breast cancer after AI + CDK4/6 inhibitor progression
MOH_2020-06-14_008801Phase 2Recruiting
- Sponsor
- Sermonix Pharmaceuticals
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Lasofoxifene with Fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Jun 2020; status: recruiting.
02
Drugs
lasofoxifenefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-06-14_008801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-14_008801.